Navigation Links
KR-9000PW Wavefront Analyzer

ProductsKR-9000PW Wavefront Analyzer
Company Topcon America Corporation
Item KR-9000PW Wavefront Analyzer
Features 
  • Measures irregular astigmatism
  • Determines if the optical aberration originates from the corneal surface or from an internal aberration such as from the lens.
  • Provides more total eye refractive data for managing your patients including those whom may consider refractive surgery.
  • Estimates the best corrected visual acuity
  • Measures post operative eye values, which many standard auto refractometers can not measure accurately.
  • Calculates estimated photopic and scotopic refractive results.
  • Assists in the refractive measurements following a patient IOL implantation.
Description The new Topcon KR-9000PW Wavefront Analyzer provides the practitioner with the most advanced and complete visual analysis system on the market today! The system incorporates a full range auto refractometer, auto keratometer, and a corneal mapping system, while adding the benefits of wavefront measurement!

The KR-9000PW combines the most reliable wavefront measurement principles (Hartmann-Shack wave-front sensor and Zernike Polynomials) with our integrated Rotary Prism technology to deliver objective data that is unmatched in accuracy and reliability. The instrument provides sphere, cylinder and axis measurements as well as indicating spherical aberrations, coma and other high order aberrations of the eye. With a measuring range of -25 to +22 diopters of sphere, the new KR-9000PW is a practical wavefront tool for use in the everyday practice.

One of the important gains provided by successful wavefront-guided corrections occurs when the pupil dilates in photopic and scotopic conditions. The value of isolating the higher order data is an excellent way of determining if surgical intervention is appropriate. The KR-9000PW is the perfect compliment to laser treatment, allowing you to learn more about the high order issues that can lead to complications.

Info Topcon America Corporation
Customer Service: (800) 223-1130
Web site: http://www.topcon.com/home.html

Related medicine products :

1. Ork Wavefront Analyzer
2. WaveScan Wavefront System
3. Velo® 300M Wavefront Lens Analyzer
4. MAXWELL Optical Wavefront Aberrometer
5. Pachymetric Analyzer Model 55
6. Humphrey Field Analyzer II - i series
7. OPD-Scan Refractive Power / Corneal Analyzer
8. OPD-Scan II Refractive Power / Corneal Analyzer
9. Coulter LH 750 Hematology Analyzer
10. Express Plus Clinical Chemistry Analyzer
11. Roche OMNI C Blood Gas Analyzer
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products:
(Date:5/21/2013)... ContinuCare Home Health, Inc. recently received a ... Disability Services. After completing a four-day review of patient ... Health was found to have no deficiencies to be ... Department of Aging and Disability Services’ mission to provide ... and opportunities that are easily accessed in local ...
(Date:5/21/2013)... 21, 2013 HealthSmart continues to grow ... presence has required the hiring of new talent in ... pleased to announce that Dawn Powell has joined the ... the Director of Account Management in the Central Region ... Irving, Texas. With extensive client management, employee benefits, and ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... York, New York (PRWEB) May 21, 2013 ... Wright Conserve hip replacement lawsuits in ... an Order in response to a request from Plaintiffs’ ... of the Defendant. The May 17th Order grants ... interviews may be conducted. (In re: Wright Medical Technology, ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving to improve the ... Creative Corridor region, is releasing results for its 2013 ... Thursday, May 23rd at 10:30 a.m. The survey ... , The survey is a critical component to the ... nurture and retain people of diverse backgrounds, cultures and ...
Breaking Medicine News(10 mins):Health News:ContinuCare Home Health, Inc. Receives Perfect Report from the Texas Department of Aging and Disability Services 2Health News:New Talent Joins the HealthSmart Account Management Team 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2
... Tips on What to Do Now as States Struggle,with ... Red Cross,chapters throughout the Midwest are keeping pace with ... landscape, despite several,chapter offices being closed due to the ... from home or using partnerships with,local government or community ...
... 11 AIDS Healthcare,Foundation (AHF) today blasted former ... for his stubbornness and,recent failure to apologize for ... in which he called for people living with,HIV/AIDS ... the time, Huckabee,told Associated Press in response to ...
... Sell Out Consumers with Unaffordable Mandate, SANTA MONICA, ... as much as 14% have led a state panel,to ... health plans. The vote,came less than a month before ... or pay penalties that increase monthly, and as,California politicians ...
... Calls on Every Candidate from Every Party to ... WASHINGTON, Dec. 11 AIDS Action released a,statement ... rewrite,his HIV/AIDS platform to ensure that the policies ... and end stigma against people,living with HIV. "Governor ...
... new study in Nature, Brandeis University Howard Hughes Medical ... curtain on the secret lives of enzymes, the ubiquitous ... a slew of sophisticated technologies to capture a key ... able to show that these proteins are not the ...
... bortezomib (Velcade) and two other drugs is showing a ... multiple myeloma, a team headed by Dana-Farber Cancer Institute ... Society of Hematology. , The three-pronged regimen of Velcade, ... has achieved an overall response rate of 98 ...
Cached Medicine News:Health News:Darkness and Cold Prevail in the Midwest 2Health News:Darkness and Cold Prevail in the Midwest 3Health News:Darkness and Cold Prevail in the Midwest 4Health News:Huckabee's Defense of Earlier, Alarmist AIDS Stance Shows Unsuitability for Presidency, Says AHF 2Health News:Double-Digit Rate Increases Expected Under Mass. Mandatory Health Law; 5% Cap on Rate Hikes Proposed 2Health News:AIDS Action Calls on Huckabee to Follow HIV/AIDS Science 2Health News:Caught in the act: The dynamic dance of enzymes 2Health News:3-drug combination 'extremely promising' as first-line therapy for multiple myeloma 2
(Date:5/21/2013)... 2013 BioElectronics Corp. (PINKSHEETS: BIEL), the ... announced that CEO, Andrew J. Whelan ... Medical Advisory Committee, Orthopedic and Rehabilitation Panel compelling ... the counter sales. "It,s been 37 ... classification schema," Whelan said.  "While the old classification ...
(Date:5/21/2013)... 2013  Janssen R&D Ireland (Janssen) today announced ... Phase 3 PROMISE study demonstrating that use of ... sustained virologic response 12 weeks after the end ... genotype 1 chronic hepatitis C adult patients with ... fibrosis, when administered once daily with pegylated interferon ...
(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ...   Changing Regulatory ... the US Market   ...
Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4